221 related articles for article (PubMed ID: 33486650)
1. Anticoagulant therapy management of venous thromboembolism recurrence occurring during anticoagulant therapy: a descriptive study.
Lai N; Jones AE; Johnson SA; Witt DM
J Thromb Thrombolysis; 2021 Aug; 52(2):414-418. PubMed ID: 33486650
[TBL] [Abstract][Full Text] [Related]
2. Treatment of DVT: how long is enough and how do you predict recurrence.
Agnelli G; Becattini C
J Thromb Thrombolysis; 2008 Feb; 25(1):37-44. PubMed ID: 17906973
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Strachan J
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
[TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolism treatment outcomes in cancer patients and effect of third-party payers on anticoagulant choice.
Jean GW; Kelly K; Mathew J; Larumbe E; Hughes R
Support Care Cancer; 2017 Jan; 25(1):59-66. PubMed ID: 27543162
[TBL] [Abstract][Full Text] [Related]
5. Venous thromboembolism in cancer patients.
Deng A; Galanis T; Graham MG
Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
[TBL] [Abstract][Full Text] [Related]
6. Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
Nicklaus MD; Ludwig SL; Kettle JK
J Oncol Pharm Pract; 2018 Apr; 24(3):185-189. PubMed ID: 29284351
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study.
Roberts MZ; Gaskill GE; Kanter-Washko J; Kyle TR; Jones BC; Bohm NM
J Thromb Thrombolysis; 2018 May; 45(4):512-515. PubMed ID: 29556958
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
Signorelli JR; Gandhi AS
J Oncol Pharm Pract; 2019 Mar; 25(2):362-368. PubMed ID: 29157146
[TBL] [Abstract][Full Text] [Related]
9. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
[TBL] [Abstract][Full Text] [Related]
10. Recurrence of Venous Thromboembolism in Patients With Cancer Treated With Warfarin.
Marshall AL; Campigotto F; Neuberg D; Rowe B; Connors JM
Clin Appl Thromb Hemost; 2015 Oct; 21(7):632-8. PubMed ID: 25850917
[TBL] [Abstract][Full Text] [Related]
11. A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer - A real world experience.
Phelps MK; Wiczer TE; Erdeljac HP; Van Deusen KR; Porter K; Philips G; Wang TF
J Oncol Pharm Pract; 2019 Jun; 25(4):793-800. PubMed ID: 29460705
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Direct Oral Anticoagulants vs. Warfarin and Recurrence After Discontinuation in Patients With Acute Venous Thromboembolism in the Real World.
Hara N; Lee T; Nozato T; Terui Matsuyama M; Okata S; Nagase M; Mitsui K; Nitta G; Watanabe K; Miyazaki R; Nagamine S; Kaneko M; Nakamura T; Nagata Y; Miyamoto T; Obayashi T; Ashikaga T
Circ J; 2022 May; 86(6):923-933. PubMed ID: 34645732
[TBL] [Abstract][Full Text] [Related]
13. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR;
Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789
[TBL] [Abstract][Full Text] [Related]
14. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy.
Douketis JD; Foster GA; Crowther MA; Prins MH; Ginsberg JS
Arch Intern Med; 2000 Dec 11-25; 160(22):3431-6. PubMed ID: 11112236
[TBL] [Abstract][Full Text] [Related]
15. Recurrent Venous Thromboembolism in Patients on Anticoagulation: An Update Based on the Revised AWMF S2k Guideline.
Klamroth R; Riess H; Beyer-Westendorf J; Linnemann B
Hamostaseologie; 2024 Apr; 44(2):150-154. PubMed ID: 38688270
[TBL] [Abstract][Full Text] [Related]
16. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
Huisman MV; Bounameaux H
Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
[TBL] [Abstract][Full Text] [Related]
17. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study.
Margaglione M; Antonucci E; D'Andrea G; Migliaccio L; Ageno W; Bucherini E; Cosmi B; Falanga A; Martini G; Mastroiacovo D; Paparo C; Poli D; Testa S; Palareti G
Blood Transfus; 2020 Nov; 18(6):486-495. PubMed ID: 32955425
[TBL] [Abstract][Full Text] [Related]
19. Short-term prognosis of breakthrough venous thromboembolism in anticoagulated patients.
van Es J; Cheung YW; van Es N; Klok FA; Dronkers CEA; Ten Wolde M; Kruip MJHA; Huisman MV; Meijer K; Kamphuisen PW; Gerdes VEA; Middeldorp S
Thromb Res; 2020 Mar; 187():125-130. PubMed ID: 31986475
[TBL] [Abstract][Full Text] [Related]
20. Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice.
Kaatz S; Fu AC; AbuDagga A; LaMori J; Bookhart BK; Damaraju CV; Tan H; Schein J; Nutescu E
Thromb Res; 2014 Oct; 134(4):807-13. PubMed ID: 25127013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
